Astrocytes are critical for neuronal redox homeostasis providing them with cysteine needed for glutathione synthesis. In this study, we demonstrate that the astrocytic redox response signature provoked by amyloid beta (Ab) is distinct from that of a general oxidant (tertiary-butylhydroperoxide [t-BuOOH]). Acute Ab treatment increased cystathionine b-synthase (CBS) levels and enhanced transsulfuration flux in contrast to repeated Ab exposure, which decreased CBS and catalase protein levels. Although t-BuOOH also increased transsulfuration flux, CBS levels were unaffected. The net effect of Ab treatment was an oxidative shift in the intracellular glutathione/glutathione disulfide redox potential in contrast to a reductive shift in response to peroxide. In the extracellular compartment, Ab, but not t-BuOOH, enhanced cystine uptake and cysteine accumulation, and resulted in remodeling of the extracellular cysteine/cystine redox potential in the reductive direction. The redox changes elicited by Ab but not peroxide were associated with enhanced DNA synthesis. CBS activity and protein levels tended to be lower in cerebellum from patients with Alzheimer's disease than in age-matched controls. Our study suggests that the alterations in astrocytic redox status could compromise the neuroprotective potential of astrocytes and may be a potential new target for therapeutic intervention in Alzheimer's disease.
Introduction

A
lzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular deposition of amyloid beta (Ab) in senile plaques and intracellular formation of neurofibrillary tangles leading to synaptic loss, neuronal death, and progressive cognitive decline (32) . Ab is a 40-42-amino acid-long peptide derived from amyloid precursor protein. The hydrophobic sequence extending from residues 25-35 in the Ab peptide are responsible for its aggregation and its neurotoxicity (38) .
Astrocytes extend between the neuronal and vascular networks and play critical roles in neurotransmitter, amino acid, energy, and volume homeostasis in brain. Astrocytes also support neuronal redox functions by providing cysteine (15) , needed for glutathione (GSH) synthesis. Although the neurotoxicity of Ab is known to be mediated in part by oxidative stress and reduced antioxidant capacity (12) , the effects of Ab on astrocytic redox metabolism are poorly characterized, despite the key role played by these glial cells in neuronal redox homeostasis under normoxic (8, 14) and stress conditions (15) . Ab activates astroglial cells, stimulating reactive oxygen species (ROS) production, which in turn causes hyperoxidation of plasma membrane proteins and lipids, impaired glutamate clearance with consequent excitotoxicity, and disruption of the mitochondrial membrane potential (3, 12) .
Cysteine limits synthesis of GSH, a major intracellular antioxidant. Cysteine can be synthesized via the transsulfuration pathway, imported into cells by a specific transporter, ASC, or derived from cystine imported by the x c -transporter (Fig. 1a) . Cystathionine b-synthase (CBS) catalyzes the rate-limiting step in the transsulfuration pathway (9) . Faced with oxidative stress conditions depleting the GSH pool, astrocytes mount an autocorrective response by activating the transsulfuration pathway and GSH biosynthesis (Fig. 1b) (47) . Mature neurons lack an efficient system for cystine uptake and rely instead on astrocytes for provision of cysteine, which is produced from secreted GSH (Fig. 1a) (14) . GSH metabolism is critically interlinked to glutamate-based neurotransmission and ion homeostasis via two transporters, x C -and X AG -, and the Na + / K + ATPase (Fig. 1a) . Aberrations at this metabolic nexus are associated with AD (26, 29) . Using indirect methods for assessing GSH, two laboratories have reported the effect of Ab 25-35 on intracellular GSH. However, their results are contradictory. Abramov et al. (2) used monochlorobimane to image GSH and reported an *50% decrease in intracellular GSH levels after 24 h of Ab treatment. In contrast, Allaman et al. (5) , using the dithionitrobenzoic acid assay, reported an *300% increase in extracellular GSH with no change in intracellular GSH levels after 48 h of Ab treatment. The mechanism of GSH extrusion and modulation of its concentration by Ab were not investigated.
In this study, we have examined the effects of acute and repeated Ab treatment on astrocytic GSH biosynthesis, redox potential, and the transsulfuration pathway and compared them with the effects elicited by tertiary-butylhydroperoxide (t-BuOOH) treatment. We find that both short and repeated Ab treatment induce a reductive redox potential in the extracellular milieu but an oxidative shift in the intracellular compartment. Acute Ab treatment increased CBS levels and enhanced transsulfuration flux in contrast to repeated Ab exposure, which decreased CBS and catalase protein levels. Further, Ab orchestrates an intracellular response, which is mechanistically distinct from that of a nonspecific oxidant, including changes in CBS and catalase protein levels and DNA synthesis that are not seen with t-BuOOH treatment. CBS levels and activity appear to be lower in the cerebellum of AD brains than in age-matched controls, indicating a pathological relevance for the ex vivo observation. These results reveal the importance of identifying disease-specific redox signatures, which could have the potential for development of metabolism-based disease-modifying therapeutic approaches.
Materials and Methods
Biological samples AD brain and age-matched control samples were from the Michigan Alzheimer's Disease Research Center Brain Bank. AD samples were derived from clinically well-characterized individuals participating in a prospective brain collection program. At death, one hemisphere was cut into 1-1.5 cm coronal slabs and frozen rapidly over liquid N 2 vapor and stored in heatsealed freezer bags at -80°C until use. The other hemisphere was fixed in 10% neutral buffered formalin and used for neuropathologic analysis. All specimens are reviewed by the same neuropathologist and diagnosis established by the Reagan-NIA criteria (13) . Age, gender, and postmortem delay-matched control specimens were derived from individuals with no clinical history of neurologic disease and normal neuropathologic examinations. Slabs were warmed to -20°C and blocs of frontal cortex and cerebellum were prepared. The University of Michigan's Committee on Use and Care of Animals approved the protocol used in this study for handling animals.
Isolation and preparation of murine primary cells
Primary murine cortical astrocytes cultures were prepared from 1-to 2-day-old Balb/c pups as described previously (20,
The effects of specific versus general oxidants on the astrocytic thiol-based redox metabolism. (a) Pathway for thiol-based redox metabolism. PPG, SAS, AbH, Aza, ACV, and MK-571 are inhibitors of c-cystathionase, c-glutamylcysteinyl synthetase, the x C -transporter, the X AG -transporter, ASC neutral amino acid transporter, c-glutamyl transpeptidase (cGT), and the multidrug resistance protein 1 (MRP1), respectively. (b) Differences in the redox responses elicited by Ab versus t-BuOOH. Green lines and fonts denote metabolites or activities that increase in response to acute or repeated treatment conditions; blue denotes a decrease under acute and repeated Ab but not t-BuOOH treatment conditions, and red denotes a decrease only with repeated Ab treatment. Black lines and text represent denote parameters in which no changes were observed. (c) Scheme showing the treatment regimens for acute versus repeated exposure to Ab or t-BuOOH. Ab, amyloid beta; AbH, aspartate-b-hydroxamate; ACV, acivicin; Aza, azaserine; PPG, propargylglycine; t-BuOOH, tertiarybutylhydroperoxide; SAS, sulfasalazine.
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. At the end of the third passage, cells were seeded in 6-well (2 · 10 6 cells/well/2 ml), 24-well (5 · 10 5 cells/well/ml), or 48-well plates (5 · 10 4 cells/well/0.4 ml), or a 8-well chamber slide (1 · 10 5 cells/well/0.4 ml), depending on the experiment, and incubated for a week (with half the medium being changed every third day). The purity of astrocytes was determined as described previously (21) and was q93%.
Dissociated neurons were prepared as described previously from embryonic day 16 (E16) to E18 mice and cultured (1 · 10 5 cells/well/0.5 ml) in neurobasal media containing B27 (1 · ) supplement, 2 mM L-glutamine and penicillin-streptomycin (100 units/ml and 100 lg/ml final concentration, respectively) on laminin (Invitrogen) and poly-D-lysine (Sigma)-coated glass cover slips (12 mm; Bellco Glass) in 24-well plates (20, 21) . The purity of neurons was assessed by staining with antibody to anti-b III tubulin (TUJ1) and found to be > 95% as observed microscopically.
Aggregation of Ab peptide
The lyophilized form of the triflouroacetate salt of the Ab peptide (25-35, or 1-42 Bachem) was aggregated as described previously (37) . Briefly, Ab was dissolved in sterile doubledistilled water as a 2 mM stock solution, incubated for 8 days at 37°C, and stored in aliquots at -80°C. Soluble Ab (2 mM) was prepared by dissolving lyophilized peptide in 1% dimethyl sulfoxide and stored immediately at -80°C.
Ab treatment of primary astrocyte cultures
At the start of experiments, astrocytes were replenished with fresh astrocyte media (Dulbecco's modified Eagle's medium/F12 + 2 mM L-glutamine + 10% heat inactivated fetal bovine serum + penicillin-streptomycin (100 units/ml and 100 lg/ml final concentration, respectively). For the acute treatment, a single bolus of 200 lM t-BuOOH or 50 lM Ab (25-35) or 10 lM Ab (1-42) was added and incubation was continued for the desired times (Fig. 1c) . For the repeated treatment model, astrocytes were stimulated with 50 lM Ab (25-35) or 10 lM Ab (1-42) repeatedly (3 bolus treatments, once every 72 h), and experimental analysis was started after the third Ab treatment (Fig. 1c) . Cell death was observed in < 10% of astrocytes after acute or repeated Ab treatment as monitored by the PI-AV labeling kit (data not shown; BioVision) and TUNEL assay kit (Roche) according to the vendor's protocol. Sulfasalazine (SAS, 500 lM), MK571 (100 lM), acivicin (400 lM), azaserine (500 lM), and aspartate-bhydroxamate (400 lM) (Sigma) when used were added in a single bolus at the start of the acute Ab treatment or the third exposure to repeated Ab treatment regimen. The effect of Ab dose on astrocyte viability and metabolite levels was determined after a single bolus treatment with 1, 10, or 50 lM Ab (acute model) or with the same Ab concentrations but administered using the repeated treatment regimen described above. To study the response of the transsulfuration pathway during acute and repeated stimulation with either t-BuOOH or Ab, cells were incubated with L-( 35 S)-methionine (Perkin Elmer) to a final concentration of 2 lCi/ml in the presence or absence of 2.5 mM propargylglycine for 6 or 12 h. At the indicated time points, culture supernatants were removed and used immediately for H 2 O 2 analysis or stored frozen at -80°C until used for determination of extracellular thiols. Cells were harvested and frozen at -80°C until further use.
CBS analysis in the human brain samples
Frozen brain tissue (*300 mg) was pulverized in liquid N 2 and CBS activity and protein expression in the postmortem brain samples of patients with AD and age-related normal subjects were analyzed as described previously (46) .
Metabolite analyses
Extracellular thiols (cystine, cysteine, and GSH) in cell culture medium were quantified in metaphosphoric acid-fixed proteinfree supernatant as described previously (20, 35) . Intracellular GSH and incorporation of ( 35 S) from methionine into GSH was quantified as described previously (20, 35) . The results were normalized to the protein concentration in each sample. Astrocytes (5 · 10 4 /well) were seeded at *50%-70% confluency in 48-well plates at day 0. After stimulation with Ab (25-35) or t-BuOOH for 2 h, cells were incubated with ( 3 H)-thymidine (1 lCi/ml; Perkin Elmer) for a further *24 h at 37°C. Cells were washed twice with phosphate-buffered saline (PBS) and dissolved in 100 ll NaOH (0.2 M). The samples were mixed with scintillation cocktail and radioactivity incorporation was measured.
Western blot analysis
Astrocytes with the indicated treatments and at the desired time points were harvested and lysed on ice as described previously (19) . Antibodies against CBS, catalase, superoxide dismutase 1 (SOD1) (Abcam), actin (Sigma), and xCT, the catalytic subunit of x C -(Novus Biological), were used to monitor expression of the respective protein antigens and detected using the Dura chemiluminescent horseradish peroxidase system (Pierce).
Determination of extracellular H 2 O 2 and intracellular ROS
Astrocytes were treated with a single bolus of the 25-35 Ab peptide for 3 and 24 h acutely or repeatedly as described above. To check the effect of antioxidant on ROS production, astrocytes were pre-treated or not with 1 mM N-acetyl cysteine (NAC) for 24 h and then incubated with Ab 25-35 (50 lM) or 1-42 (10 lM) for 3 h. Alternatively, astrocytes were transfected with catalaseHis-V5-expressing pCDNA3.1 (a generous gift from Brent Carter, University of Iowa) or the empty pCDNA3.1 plasmid using TransIT-2020 reagent (Mirus) as per the manufacturer's protocol. After 24 h post transfection, cells were incubated with Ab 25-35 (50 lM) or 1-42 (10 lM) in fresh media for 3 h. After Ab stimulation, the astrocyte conditioned medium was saved for extracellular H 2 O 2 determination, whereas the cells were used for intracellular ROS detection using the Image-iT Live Green ROS Detection Kit as per the manufacturer's protocol (Invitrogen). Briefly, cells were washed twice with Ca 2 + -and Mg 2 + -free Hank's balanced salt solution (HBSS), followed by incubation with 5-(and-6)-carboxy-2¢,7¢-dichlorodihydrofluorescein diacetate (Invitrogen) at a final concentration of 5 lM for 30 min at 37°C. Cells were washed once with HBSS and incubated with Hoechst 33342 nuclei stain (1:200 dilution, excitation 365 nm, emission 480 nm; Invitrogen) for 10 min at 37°C to ensure equal cell numbers. Cells were washed three times with HBSS followed by lysing using the lysis buffer. An aliquot of lysate (100 ll each) was transferred to a fluorimetric plate, the fluorescence excitation/emission maxima were recorded at 495/529 nm and the results expressed as F529/F480 nm. The concentration of H 2 O 2 in the conditioned media was measured using the Amplex Red reagent kit as per the manufacturer's protocol (Molecular Probe). Conditioned media (100 ll) in a 96-well fluorimetric plate was mixed with 10 lM Amplex red reagent and 1 U/ml horseradish peroxidase at a 1:1 ratio and incubated for 30 min at room temperature. A standard curve was generated with known concentrations (50 nM to 10 lM) of H 2 O 2 . The amount of resorufin produced by Amplex Red oxidation was determined fluorimetrically (excitation: 544 nm, emission: 590 nm). Background fluorescence was determined for the medium control and subtracted from each value and results were expressed as the concentration of H 2 O 2 in the medium.
Analysis of apoptosis
The terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) assay (Roche Diagnostics) was employed as previously described (20) . Briefly, astrocytes were cultured in 24-well plates and treated acutely or repeatedly with 50 lM (25-35) or 10 lM (1-42) Ab as described above. After incubation, 500 ll of each conditioned media was transferred on to neuronal monolayers in 250 ll neuronal media in the presence or absence of 50 lM Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Neurons were incubated for another 12-14 h followed by labeling with the TUNEL stain. To check the effect of Ab or t-BuOOH on viability, astrocytes were treated with different concentrations of Ab (25-35) peptide (1, 10, 50 lM) or t-BuOOH (200, 400, 800 lM) for 12-14 h followed by labeling with the TUNEL stain. Nuclei were observed with Hoechst stain (1:200 dilution, excitation 365 nm, emission 480 nm; Invitrogen) and quantitative analysis was performed by counting > 2000 cells as described previously (20) .
Analysis of mitochondrial activity
To check the effect of Ab on astrocytic mitochondrial activity, the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed as previously described (47) . In brief, astrocytes (1 · 10 6 /well) in 24-well plates were treated with different concentration of Ab (25-35) acutely or repeatedly. After stimulation for *20 h, cells were washed with PBS and incubated with MTT dye (0.5 mg/ml) for 2 h at 37°C, followed by washing with PBS. Cells were dissolved in dimethyl sulfoxide. Optical density was measured at 553 nm and the background was corrected after reading the absorbance at 650 nm.
Statistical analyses
The significance of the differences in data between control and experimental groups was determined by one-way analysis of variance followed by post-test Bonferroni adjustment. Students t-test (paired, two-tailed) was also performed for comparison with the analysis of variance test. p < 0.05 was considered to be statistically significant.
Results
Protracted increase in astrocytic ROS production by Ab
Since the kinetics of Ab-induced ROS production by astrocytes and microglia have previously been monitored only on a short time scale (3, 24) , we examined the intracellular ROS and extracellular H 2 O 2 levels on a longer time scale during which metabolic changes are typically observed (Fig. 2) . Acute Ab treatment was reported to induce an *2-fold increase in ROS levels 30 min after exposure (3). We found similarly increased ROS levels even at 3 h after acute Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) exposure, but the levels declined to control values after 24 h (Fig. 2a) . In contrast, intracellular ROS levels were *3-and *5-fold higher at the same times after the last Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) addition in the repeated treatment regimen (Fig. 2a) . Since ROS are typically short-lived, these results reveal that both acute and repeated Ab-treatment regimens provoke sustained ROS production spanning several hours. ROS production is paralleled by increased extracellular H 2 O 2 , with the kinetics of H 2 O 2 increase and dissipation varying with the treatment regimen. Extracellular H 2 O 2 levels were *4-fold higher after 24 h of acute and *2-fold higher after 24 h of repeated Ab treatment (Fig. 2b) . The longer Ab (1-42) peptide increased intracellular ROS by *50% and extracellular H 2 O 2 by *65% after 3 h of treatment (Fig. 2c, d) . Addition of the antioxidant, NAC, a cysteine precursor, or over expression of catalase, a peroxide scavenger, decreased Ab-mediated over production of ROS (Fig. 2c, e ) and H 2 O 2 ( Fig. 2d, f) . When freshly prepared 50 lM Ab (25-35) was used instead of the aggregated form, it failed to induce over production of intracellular ROS and extracellular H 2 O 2 ( Fig. 2g, h ). Catalase, SOD, and GSH peroxidase are major antioxidant enzymes in mammalian cells that clear ROS. We checked the expression levels of two of these antioxidant enzymes and found that repeated but not acute Ab (25-35) treatment decreased steady-state levels of catalase, whereas Cu/Zn SOD1 was unchanged by either treatment (Fig. 2i) . In contrast, neither acute nor chronic t-BuOOH treatment affected catalase or SOD1 expression levels (Fig. 2i) . Since the magnitude of ROS stimulation seen with Ab (25-35) and (1-42) was similar, and NAC similarly abrogated ROS accumulation, further experiments were conducted with the shorter peptide.
Differential responses in transsulfuration and GSH synthesis pathways to acute versus repeated Ab treatment
One mechanism by which human astrocytes respond to oxidative stress induced by t-BuOOH is by increasing flux through the transsulfuration pathway (47) , which furnishes cysteine and results in increased GSH synthesis. In murine astrocytes, acute t-BuOOH or acute Ab (25-35) stimulation also induced GSH synthesis at levels that were comparable at 6 and 12 h (Fig. 3a) . When freshly prepared 50 lM soluble Ab (25-35) was used, no change in GSH levels was observed at 6 h (Fig. 3b ). An *50% increase in radiolabel incorporation from ( 35 S)-methionine to GSH was observed in 6 h upon acute t-BuOOH or acute Ab stimulation (Fig. 3c ) that was inhibited *2-fold by propargylglycine, a suicide inhibitor of ccystathionase, the second enzyme in the transsulfuration pathway (Fig. 1a) , demonstrating the role of this pathway in the astrocytic response to acute oxidative challenge. In contrast, GSH levels were unchanged by repeated treatment with either t-BuOOH or Ab (25-35) after 6 h and diminished *20% with Ab after 12 h (Fig. 3a) . Repeated Ab treatment (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) resulted in an *2-fold decrease in the transsulfuration flux (Fig. 3d) . Glutathione disulfide (GSSG) levels were *3-fold higher in response to t-BuOOH at 6 h but normalized to control levels at 12 h (Fig. 3e) . In contrast, acute Ab treatment (25-35) caused a slower increase in GSSG levels, which were 20% higher at 6 h and twofold higher at 12 h in comparison to the untreated control. An effect on the GSSG concentration was not observed with repeated t-BuOOH and Ab treatment. As a result of the varied responses in the GSH and GSSG pool with different treatments, the GSH:GSSG ratio, an indicator of the intracellular redox poise, initially decreased in response to acute (*30%) and repeated (*50%) t-BuOOH treatment at 6 h but subsequently overshot control values at 12 h (Fig. 3f) . In contrast, both acute and repeated Ab treatments resulted in an oxidative shift in the intracellular GSH/GSSG ratio.
CBS catalyzes the committing step in the transsulfuration pathway and Western blot analysis revealed that CBS protein levels increase in response to acute treatment with Ab (25-35) but decrease in response to repeated treatment (Fig. 3g) . In contrast, neither acute nor repeated t-BuOOH affected CBS levels. Hence, the astrocytic redox responses to Ab versus an organic peroxide challenge and to acute-versus repeated exposure to Ab are distinct.
Ab induces oxidative remodeling of the intracellular GSH/GSSG redox potential
The GSH/GSSG potential is initially slightly oxidized at 6 h in response to acute ( -241 mV) and repeated ( -244 mV) tBuOOH treatment compared with control ( -247 mV) but subsequently overshoots the control value by appoximately -10 mV at 12 h (Fig. 3h) . In contrast, acute Ab treatment (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) results in an oxidative shift in the GSH/GSSG potential to -237 mV at 12 h, whereas repeated Ab treatment elicits the same change within 6 h.
Ab induces reductive remodeling of the extracellular cysteine/cystine redox potential
The cysteine:cystine ratio is a key determinant of the extracellular redox poise (33) . Hence, the kinetics of extracellular cystine consumption and cysteine accumulation were monitored and were strikingly more rapid in the presence of Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) than in untreated controls (Fig. 4a, b) and dependent on the dose of Ab (Fig. 5a, b) . Ab (1-42) caused similar changes in cysteine and cystine (data not shown). Levels of xCT, the catalytic subunit of the primary cystine transporter, x C -, were not affected by acute Ab (25-35) treatment but were downregulated > 4-fold with repeated Ab treatment (Fig. 4c) . Neither acute nor repeated t-BuOOH treatment influenced xCT levels (Fig. 4c) or affected cystine consumption significantly (data not shown). The cysteine/cystine redox couple is important for controlling the redox poise in the extracellular space. The extracellular cysteine/cystine redox potential in untreated cells was estimated to be appoximately -80 mV at 2 h. After 6 h of culture, the redox potential decreased to -90 mV (untreated controls) versus -105 mV (acute Ab treatment) and -124 mV (repeated Ab treatment), indicating a more reducing environment (Fig. 4d) and the magnitude of the reductive shift was dependent on the dose of Ab (Fig. 5c) . As expected, t-BuOOH caused cysteine oxidation and the redox potential increased to a more positive value at 2 h but normalized to control values in 6 h (Fig. 4d) . Neither acute nor repeated t-BuOOH treatment altered the extracellular GSH concentration, whereas a time-dependent increase in extracellular GSH was observed in response to Ab treatment (Fig.  4e) , which was dependent on the dose of Ab (Fig. 5d) . Thus, the metabolic response both inside and outside the cell to Abinduced increase in ROS levels results in reductive remodeling in the extracellular compartment.
Ab induces DNA synthesis
Since a reductive shift in the extracellular potential is usually correlated with cell proliferation, the effect of Ab (25-35) on DNA synthesis was assessed. Like dendritic cells that remodel the extracellular redox potential to support T cell proliferation (49), the astrocytic response to Ab might similarly stimulate a proliferative glial response. Acute Ab treatment increased ( 3 H)-thymidine incorporation into DNA by *50% (Fig. 6 ) as seen previously (27) , while a robust 300% increase was observed with repeated Ab treatment. In contrast, t-BuOOH decreased ( 3 H)-thymidine incorporation into DNA modestly when applied as a single bolus, whereas repeated t-BuOOH treatment resulted in a 200% decrease (Fig. 6 ).
Intracellular GSH is source of extracellular cysteine
Extracellular cysteine is derived from the breakdown of secreted GSH via the c-glutamyl pathway (49) . To establish the involvement of this pathway in the astrocytic response to Ab (25-35), we employed pharmacological inhibition at various steps (Fig. 1a) . Inhibition of cystine import with SAS, GSH export with MK-571, or extracellular GSH cleavage with acivicin significantly decreased extracellular cysteine accumulation (Fig. 7a) . In contrast, inhibition of X AG -, which has a low affinity for cysteine, or inhibition of ASC, the neutral amino acid transporter, did not have a significant effect on extracellular cysteine accumulation. Of these inhibitors, only SAS and to a smaller extent, MK-571, diminished cystine consumption from the medium (Fig. 7b) . whereas the decrease in cystine consumption in the presence of SAS is expected, the effect of MK-571 might be indirect, that is, by inhibiting GSH efflux, it inhibits cystine uptake.
Ab does not cause astrocytic apoptosis but decreases mitochondrial activity
Ab-mediated cellular toxicity and apoptosis are reported in AD (3, 5, 6) and primary neurons are very sensitive to Abinduced apoptosis. Astrocytes exposed to 50 lM Ab (25-25) 
2390
are resistant to apoptosis after exposure to Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) as monitored by the TUNEL (Fig. 8a) or Annexin-V (data not shown) assays. In contrast, 800 lM t-BuOOH induced apoptosis in *80% of the astrocytes but not at 400 lM (not shown) as measured using the TUNEL assay. Interestingly, the MTT assay, a reporter of mitochondrial activity, showed a dose-dependent decrease (*10%-35%) in response to Ab (25-35) treatment, which was concentration dependent (Fig. 8b) . 
SPECIFIC Ab-INDUCED REDOX CHANGES
Repeated Ab treatment abrogates the neuroprotective effect of astrocytes
Cysteine enhances GSH synthesis in neurons and is a known neuroprotectant (15) . Since Ab stimulates extracellular cysteine accumulation by astrocytes, the effect of astrocyteconditioned media on protecting neurons from Ab-induced apoptosis was examined. For this, astrocytes were stimulated acutely or repeatedly with 50 lM Ab (25-35) or 10 lM Ab (25-35) as described under the Materials and Methods section and after 12-14 h of incubation, conditioned medium was removed and transferred onto neuronal monolayers in the presence or absence of 50 lM Ab for 12-14 h after which apoptosis was assessed by the TUNEL assay (Fig. 9) . Unlike astrocytes that were not found to undergo apoptosis in response to 50 lM Ab treatment (Fig. 8a) , *50% neuronal cell death was observed. Conditioned medium from untreated or acutely treated astrocyte cultures afforded similarly modest but significant protection of neurons from apoptosis compared with fresh medium (Fig. 9a, b) . In contrast, when conditioned medium from astrocyte cultures exposed to repeated Ab treatment was used, the neuroprotective effect was abrogated (Fig. 9a, b) . The effect of astrocyte-conditioned medium from cultures that had received either acute or repeated Ab treatment regimens on survival of neurons that had not been exposed to Ab was assessed (Fig. 9c) . Conditioned media from either untreated or acutely treated astrocytes (with either Ab 25-35 or 1-42) did not cause neuronal toxicity. However, conditioned media from astrocytes exposed to the repeated Ab regimen caused significant neuronal apoptosis (Fig. 9c) . Notably, the extent of chronic Ab 1-42-mediated apoptosis was considerably lower than for Ab 25-35 (Fig. 9c) .
Changes in CBS levels and activity in AD brain
Immunohistochemical localization of CBS in adult murine brain reveals weak and diffuse labeling with the exception of the hippocampus and cerebellum, where the labeling is intense (42) . Since cerebellar and cortical tissues from AD patients and age-matched controls were more readily available than hippocampal tissue, we compared CBS activity and protein levels in these samples (Fig. 10) . Although differences were not observed in the frontal cortex, cerebellum from AD patients tended to exhibit both lower CBS expression (Fig.  10a, b) and activity (Fig. 10c) . However, due to high variations and relatively low sample number, the difference did not reach statistical significance. Moreover, differences in CBS protein level and activity between AD and healthy subjects did not correlate with sex, age, and postmortem time of the individual specimens (Supplementary Table S1 ; Supplementary Data are available online at www.liebertonline.com/ars).
Discussion
While oxidative stress is a nonspecific hallmark of many neurodegenerative diseases (6), the sequelae of specific redox potential changes in the intra-versus extra-cellular compartments that govern disease-specific signaling and metabolic responses are unknown. Since H 2 O 2 is reported to mediate Ab toxicity (11), we investigated thiol-based redox responses of astrocytes to Ab versus the organic peroxide, t-BuOOH, and discovered that they elicit significantly different effects (Fig. 1b) .
Cellular functions such as proliferation, differentiation, and death signals are modulated in part by the intracellular and extracellular redox potentials (43) . Mammalian cells have multiple redox buffering systems (22) . The redox potential of the extracellular compartment is regulated dynamically by intracellular redox metabolism, and, in contrast to the importance of the GSH/GSSG redox couple inside the cell, the cysteine/cystine redox pair is quantitatively the most significant thiol-based redox buffer outside the cell (33) . A reductive shift (i.e., to a more negative redox potential value) is associated with cellular proliferation, whereas an oxidative shift correlates with cell death (33) . Our results, that is, that Ab treatment induces a reductive shift, in contrast to a general oxidant, in the extracellular redox potential in astrocytic cultures, suggest that a similar response in the CNS might stimulate proliferation of microglia, exacerbating neuronal degeneration. In fact, inflammation is considered to contribute to neuronal demise in AD (4).
Our study also reveals that the astrocytic redox response to Ab stimulation is complex and distinct in the intra-versus extracellular compartments. Paradoxically, elevated H 2 O 2 levels are observed under conditions where there is a net shift in the extracellular redox potential in the reductive direction in response to Ab treatment (Figs. 3-5) , emphasizing the importance of analyzing metabolic responses to oxidative stress in the context of the redox milieu in addition to the levels of the individual oxidant species. Ectodomains of membrane proteins are rich in disulfide bonds, and the *30 mV decrease in redox potential induced by repeated Ab treatment (Figs. 4 and 5 ) is expected to result in a 10-fold shift in the equilibrium from the disulfide to the dithiol state. The redox state of receptors and transporters influence both their structure and function and the Ab-induced reductive shift is likely to have pleiotropic consequences on signaling pathways emanating from redoxsensitive membrane protein targets that await elucidation.
An interesting parallel in extracellular reductive remodeling is seen with dendritic cells during activation of T cells and results from increased cystine consumption and extracellular cysteine secretion without enhanced transsulfuration flux (49) . The released cysteine is used by naïve T cells, which, like neurons, are unable to efficiently transport cystine. In the CNS, cysteine accumulation, if unchecked, might lead to N-methyl D-aspartate receptor excitoxicity (36) . We speculate that the threshold between a neuroprotective versus toxic concentration of cysteine may be crossed if astrocytes are overactivated by repeated Ab stimulation. As previously shown with dendritic cells, the c-glutamyl cycle is also the source of extracellular GSH and cysteine in astrocytes (49) . Inhibition of the x C -antiporter, the GSH exporter or c-glutamyltranspeptidase all lead to lower extracellular cysteine accumulation (Fig. 7a) . While secretion of extracellular thioredoxin by dendritic cells during T cell activation was proposed to contribute to cysteine accumulation (7), subsequent studies have ruled out a role for thioredoxin in this process (49) . Additional redox systems not examined in this study are also likely to contribute to the redox remodeling induced by Ab, For instance, a Cu-Zn-type extracellular SOD has been shown to delay oxidation of extracellular GSH (45) .
The profiles of intracellular redox responses elicited by acute versus repeated exposure to Ab are also distinct from the corresponding response triggered by t-BuOOH (Fig. 1b) . Astrocytes responded to peroxide treatment by a compensatory increase in GSH synthesis, without affecting CBS enzyme level, leading to a net reductive shift in the intracellular GSH/ GSSG potential (Fig. 3) . Although t-BuOOH treatment does not affect CBS levels, flux through the transsulfuration flux is increased and could result from changes either up-or downstream of CBS, which remain to be elucidated. The GSH:GSSG ratio is initially diminished in response to acute (*30%) and chronic (*50%) t-BuOOH treatment at 6 h but subsequently overshoots the control values at 12 h (Fig. 3h) . In an autocorrective response, cells increase GSH synthesis to counter oxidative stress, leading to more reducing redox potential at 12 h. Cells treated repeatedly with t-BuOOH show a different response, that is, lower GSSG levels (Fig. 3e) . The net result, nevertheless, is more reducing conditions.
In contrast, both acute and repeated Ab treatment resulted in an oxidative shift in the GSH/GSSG redox potential. With acute Ab treatment, the decline in the redox potential was driven by the time-dependent increase in GSSG levels, whereas with repeated Ab treatment, the concentration of GSSG increased transiently before returning to control levels (Fig. 3e) . However, the concentration of reduced GSH also The average CBS protein levels (n = 8), and (c) the average CBS activity in postmortem samples of frontal cortex (n = 10) and cerebellum (n = 12 and 16 for normal and AD samples respectively), obtained from AD patients and agematched normal individuals. The CBS protein levels were quantified from Western blots. AD, Alzheimer's disease. decreased over time with chronic Ab treatment, which resulted in a lower redox potential. The difference between the acute versus repeated response to Ab suggests that metabolic adaptation occurs during prolonged Ab treatment that results in lowering of the GSSG pool. Since the astrocytic GSH pool also serves as an important cysteine reservoir for supporting neuronal GSH synthesis via secretion and cleavage, the smaller GSH pool size due to extended Ab exposure could compromise this neuroprotective function of astrocytes.
CBS protein levels were diminished after repeated Ab but not peroxide treatment (Fig. 3g) . A similar trend was observed in cerebellar CBS levels and activity in AD versus control samples, but did not reach statistical significance (Fig. 10) . This could have resulted from large inter-individual variations, the relatively small sample size as well as sample heterogeneity, that is, if decreased CBS were restricted to astrocytes in AD, the difference would be underestimated in tissue samples due to the presence of nonastrocytic cells. Since CBS plays an important role both in GSH-linked redox homeostasis (10, 35) and in H 2 S biogenesis (44), reduced expression of this protein in AD brain if seen might be significant in disease pathology. H 2 S, which modifies long-term potentiation (1) , is reported to be severely depressed in AD brain (17) . In addition, levels of S-adenosylmethionine, an allosteric activator (18) and stabilizer (39) of CBS, are decreased in AD brain, but not in idiopathic Parkinson's disease patients, suggesting that the change is not generally correlated with a chronic neurodegenerative disease but may be AD specific (34) . Hence, upregulation of CBS expression or its activation or stabilization might represent a specific therapeutic strategy for alleviating redox perturbations associated with AD.
NAC treatment or catalase overexpression abrogated the Ab-induced ROS generation (Fig. 2) . Catalase or SOD overexpression have been shown to decrease ROS levels and rescue neurons from the toxic action of the Ab peptide (16, 30) , consistent with overproduction of ROS contributing to neurotoxicity. Our finding that catalase but not SOD1 levels were diminished after repeated Ab treatment is consistent with the earlier observation that brain catalase but not SOD activity is decreased in patients with Alzheimer's type dementia (23, 40) . Ferritin and catalase are potent suppressors of Ab toxicity (41) . For to be effective against Ab-induced ROS accumulation, downstream antioxidant enzymes such as catalase and/ or GSH peroxidase, which remove H 2 O 2 , the product of SOD, need to be also act in concert. A direct effect of Ab on catalase has been shown, which resulted in deactivation of catalase and increased cellular intracellular H 2 O 2 (25) . Although some studies report decreased SOD activity (31, 48) , others report either no change (23, 40) or increased SOD activity in AD patients compared with controls (28) .
Clearly, the Ab effects on redox homeostasis are more complex than simply being mediated via peroxide as proposed (11) . The aim of the present study was to determine differences, if any in astrocytic responses to a specific (e.g., Ab) versus a general (e.g., t-BuOOH) oxidant insult. In the present study, we report for the first time, a detailed mechanistic analysis of the redox changes in astrocytes in response to Ab treatment. Although Ab treatment stimulates H 2 O 2 /ROS production in astrocytes, the intra-and extra-cellular metabolic responses are distinct from those of a nonspecific oxidant, and await full mechanistic elucidation. In summary, our study points to the importance of identifying AD-specific redox markers that might be etiologically important and could serve as potential therapeutic targets.
